MT-2 is frequently described as a close relative of MT-1. Pharmacologically that framing is misleading. The two peptides differ in the property that matters most for a receptor ligand: how many receptors they activate.
For a direct comparison, see our Melanotan 1 vs Melanotan 2 article. This piece focuses on MT-2 specifically.
What MT-2 is
MT-2, or melanotan II, is a cyclic heptapeptide analogue derived from alpha-melanocyte-stimulating hormone. The cyclisation is structurally important: constraining the peptide into a ring restricts its conformational freedom, which increases both its metabolic stability and its receptor affinity compared with the linear native hormone.
That same conformational constraint is why it binds broadly. The ring presents a shape that several melanocortin receptor subtypes recognise.
Receptor promiscuity
Where MT-1 is comparatively MC1R-selective, MT-2 is a non-selective melanocortin agonist. It has meaningful activity at MC1R, MC3R, MC4R and MC5R. Because those receptors sit in different tissues and govern unrelated processes, a single application of MT-2 engages several systems simultaneously.
This is the defining experimental characteristic of the compound, and it cuts both ways. For a researcher studying melanocortin signalling broadly, that breadth is useful. For anyone trying to attribute an observed effect to one receptor, it is a serious confound. Any MT-2 study without receptor-selective antagonists or knockout controls will struggle to isolate mechanism.
What the published research examines
Energy balance and feeding
The largest body of MT-2 research concerns MC4R and feeding behaviour in rodent models. Raposinho and colleagues examined its interaction with neuropeptide Y signalling in the male rat, distinguishing effects on feeding from effects on the gonadotropic and somatotropic axes.[2]
A 2015 study in Frontiers in Behavioral Neuroscience found that the inhibitory effect on feeding in rats depended on dietary fat content rather than obesity status.[3] That kind of result is a useful corrective: it shows the response is conditional on experimental context rather than being a fixed property of the compound.
Neuroprotection and nerve regeneration
Ter Laak and colleagues reported that MT-2 promoted peripheral nerve regeneration and showed neuroprotective properties in the rat.[1] This line of work sits well outside the pigmentation context the compound is usually associated with, and it illustrates how broadly melanocortin receptors are distributed.
Thermogenesis
A 2021 paper in Experimental Physiology examined MT-2 in mice deficient in pituitary adenylate cyclase-activating polypeptide, reporting partial rescue of impaired thermogenic capacity.[4] Genetic models of this kind are among the more informative designs in melanocortin research, because they isolate a pathway rather than relying on pharmacology alone.
Handling and stability
MT-2 is supplied as a lyophilised solid and stored at −20°C, protected from light and moisture. Reconstitution uses sterile solvent added slowly down the vial wall with gentle swirling.
Cyclic peptides are generally more robust than their linear equivalents, since the ring structure resists exopeptidase attack. That relative stability should not be mistaken for indifference to handling: reconstituted material still degrades through repeated freeze-thaw cycles, and aliquoting at the point of reconstitution remains good practice.
What the literature does not establish
Because MT-2 acts across multiple receptors, mechanistic claims attributing a result to one receptor subtype are rarely supported by the study design that produced them. Much of the literature is also in rodent models, and melanocortin receptor distribution differs between species, so cross-species extrapolation is not straightforward.
Reported effects frequently vary with diet, genetic background and housing conditions, which is itself a finding worth taking seriously when designing experiments.
References
- Ter Laak MP. The potent melanocortin receptor agonist melanotan-II promotes peripheral nerve regeneration and has neuroprotective properties in the rat. European Journal of Pharmacology. 2003. PMID 12591111
- Raposinho PD. The melanocortin agonist Melanotan-II reduces the orexigenic and adipogenic effects of neuropeptide Y (NPY) but does not affect the NPY-driven suppressive effects on the gonadotropic and somatotropic axes in the male rat. Journal of Neuroendocrinology. 2003. PMID 12535159
- van den Heuvel JK. Inhibitory Effect of the Melanocortin Receptor Agonist Melanotan-II (MTII) on Feeding Depends on Dietary Fat Content and not Obesity in Rats on Free-Choice Diets. Frontiers in Behavioral Neuroscience. 2015. PMID 26733840
- McMillan TR. Melanotan II, a melanocortin agonist, partially rescues the impaired thermogenic capacity of pituitary adenylate cyclase-activating polypeptide deficient mice. Experimental Physiology. 2021. PMID 33332767
Research use only
MT-2 is supplied by MMpeptides strictly for laboratory and in vitro research. It is not approved for human or veterinary use, is not a cosmetic or medicinal product, and nothing in this article should be read as describing use in people. Third-party studies are cited for scientific context only. Researchers are responsible for observing all applicable regulations in their jurisdiction.